<DOC>
	<DOCNO>NCT01476800</DOCNO>
	<brief_summary>The purpose study assess pharmacokinetic interaction multiple-dose ketoconazole single-dose YM178 OCAS safety tolerability YM178 OCAS alone combination ketoconazole healthy adult volunteer .</brief_summary>
	<brief_title>A Study Assess Pharmacokinetic Interaction Multiple Dose Ketoconazole Single Dose YM178 Oral Controlled Absorption System ( OCAS ) Healthy Adult Volunteers</brief_title>
	<detailed_description>A single oral dose YM178 OCAS administer 2 separate occasion : alone Day 1 Period 1 multiple- dose ketoconazole Day 4 Period 2 . In Period 2 , oral dose ketoconazole administer daily Days 1-9 .</detailed_description>
	<mesh_term>Mirabegron</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<criteria>The subject , female , must surgically sterile ( must document ) , postmenopausal ( define least two year without menses ) , must use doublebarrier contraception nonhormonal IUD The subject , female , must nonlactating , negative serum pregnancy test result study The subject must good health The subject must weigh least 45 kg , Body Mass Index ( BMI ) 18 30 kg/m^2 , inclusive The subject must normal clinical laboratory test result , abnormal , clinically significant The subject must normal 12lead electrocardiogram ( ECG ) ( include normal interval duration ) . If abnormal , interval duration must deem clinically significant must exceed follow value : PR interval must exceed 220 millisecond QTc value must exceed 450 millisecond Males 470 millisecond females The subject must negative drug alcohol toxicology screen study . Any subject test positive drug alcohol study terminate The subject history clinically significant illness ( e.g. , cardiovascular , hepatic , renal , gastrointestinal abnormality within past 3 month would preclude participation study The subject know hepatitis positive hepatitis A antibody IgM , hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) antibody , positive result test HIV1 and/or HIV2 antibodies The subject know hypersensitivity YM178 , ketoconazole imidazole compound The subject rest supine pulse &lt; 50 bpm &gt; 90 bpm The subject orthostasis ( change pulse rate orthostatic maneuver &gt; 20 bpm level â‰¥ 120 bpm ) The subject take oral hormonal contraceptive The subject take potential inhibitor CYP3A4 CYP2D6 The subject receive anticipated receive prescription systemic topical medication within past 14 day longactive treatment ( e.g. , depot formulation ) within past 30 day The subject receive otherthecounter medication include herbal medicine within past 14 day ( occasional use acetaminophen 2000 mg/day 4 day per week permit ) The subject currently participate another clinical trial and/or take take investigational drug past 30 day ( 10 halflives drug , whichever longer ) The subject anticipate inability abstain alcohol , caffeine use , grapefruit grapefruit juice 48 hour prior administration first dose YM178 Day 1 Period 1 throughout duration study The subject use tobaccocontaining product nicotine nicotinecontaining product past six month The subject consume 5 unit alcoholic beverage ( one unit 12 ounce beer , 4 ounce wine 1 ounce spirit ) per week history substance abuse , drug addiction , alcoholism within past 2 year . The subject blood donation significant loss blood receive transfusion blood blood product within 56 day study initiation donate plasma within 7 day study initiation . The subject history psychiatric illness within past 10 year incapable compliant study procedures The subject unable understand verbal and/or write English language certify translation inform consent available The subject history benign prostatic hypertrophy urinary incontinence</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Drugs , Investigational</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>Urinary Bladder , Overactive</keyword>
	<keyword>YM178</keyword>
	<keyword>Mirabegron</keyword>
</DOC>